Capricor Therapeutics (CAPR) 10-Q 15 May 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	12-May-14
Document Information [Line Items]	'	'
Entity Registrant Name	'CAPRICOR THERAPEUTICS, INC.	'
Entity Central Index Key	'0001133869	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'CAPR	'
Entity Common Stock, Shares Outstanding	'	11,690,859
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Period Focus	'Q1	'
Document Fiscal Year Focus	'2014	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2014	Dec. 31, 2013
CURRENT ASSETS	'	'
Cash and cash equivalents	$12,979,150	$1,729,537
Marketable securities	326,226	326,494
Restricted Cash	555,232	1,401,859
Interest receivable	757	187
Prepaid expenses and other current assets	169,579	222,763
TOTAL CURRENT ASSETS	14,030,944	3,680,840
PROPERTY AND EQUIPMENT, at cost	'	'
Furniture and equipment	38,850	38,850
Laboratory equipment	208,667	115,766
Property, Plant and Equipment, Gross	247,517	154,616
Less accumulated depreciation	-83,978	-80,429
NET PROPERTY AND EQUIPMENT	163,539	74,187
OTHER ASSETS	'	'
Patents, net of accumulated amortization of $33,557 and $32,475 respectively	228,382	227,207
Loan fees, net of accumulated amortization of $8,556 and $6,722, respectively	28,111	29,945
In-process research and development, net of accumulated amortization of $0	1,500,000	1,500,000
Deposits	25,728	25,728
TOTAL ASSETS	15,976,704	5,537,907
CURRENT LIABILITIES	'	'
Accounts payable and accrued expenses	1,518,595	1,506,509
Accounts payable and accrued expenses, related party	481,643	382,142
Sub-award payable, related party	0	41,855
Accrued royalties	132,379	122,416
Deferred income, current	4,166,667	0
TOTAL CURRENT LIABILITIES	6,299,284	2,052,922
LONG-TERM LIABILITIES	'	'
Deferred income, net of current portion	7,291,666	0
Loan payable	3,961,733	3,961,733
Accrued interest	83,461	58,134
TOTAL LONG-TERM LIABILITIES	11,336,860	4,019,867
TOTAL LIABILITIES	17,636,144	6,072,789
STOCKHOLDERS' EQUITY (DEFICIT)	'	'
Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.001 par value, 50,000,000 shares authorized, 11,690,859 and 11,687,747 shares issued and outstanding respectively	11,690	11,687
Additional paid-in capital	15,638,420	15,552,946
Accumulated other comprehensive loss	-404	-980
Deficit accumulated during the development stage	-17,309,146	-16,098,535
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	-1,659,440	-534,882
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$15,976,704	$5,537,907

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Patents, net of accumulated amortization (in dollars)	$33,557	$32,475
Loan fees, net of accumulated amortization (in dollars)	$8,556	$6,722
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	11,690,859	11,687,747
Common stock, shares outstanding	11,690,859	11,687,747

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	3 Months Ended		105 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
INCOME	'	'	'
Collaboration income	$1,041,667	$0	$1,041,667
Grant income	0	233,291	4,180,970
TOTAL INCOME	1,041,667	233,291	5,222,637
OPERATING EXPENSES	'	'	'
Research and development	1,374,757	1,191,154	12,874,352
General and administrative	852,347	474,429	7,806,014
TOTAL OPERATING EXPENSES	2,227,104	1,665,583	20,680,366
LOSS FROM OPERATIONS	-1,185,437	-1,432,292	-15,457,729
OTHER INCOME (EXPENSE)	'	'	'
Investment income (loss)	153	18,889	151,044
Interest expense	-25,327	-3,711	-83,461
Impairment of goodwill	0	0	-1,919,000
TOTAL OTHER INCOME (EXPENSE)	-25,174	15,178	-1,851,417
NET LOSS	-1,210,611	-1,417,114	-17,309,146
OTHER COMPREHENSIVE GAIN (LOSS)	'	'	'
Net unrealized gain (loss) on marketable securities	576	-8,763	-404
COMPREHENSIVE LOSS	($1,210,035)	($1,425,877)	($17,309,550)
Net loss per share, basic and diluted	($0.10)	($0.14)	'
Weighted average number of shares, basic and diluted (in shares)	11,689,441	10,351,294	'

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Subcription receivable [Member]	Other Comprehensive Loss [Member]	Accumulated Deficit during Development Stage [Member]
Balance at Jul. 04, 2005	$0	$0	$0	$0	$0	$0
Balance (in shares) at Jul. 04, 2005	'	0	'	'	'	'
Issuance of stock	0	3,735	-1,935	-1,800	0	0
Issuance of stock (in shares)	'	3,734,740	'	'	'	'
Interest on subscription receivable	-36	0	0	-36	0	0
Net loss	36	0	0	0	0	36
Balance at Dec. 31, 2005	0	3,735	-1,935	-1,836	0	36
Balance (in shares) at Dec. 31, 2005	'	3,734,740	'	'	'	'
Issuance of stock	3,008,000	1,950	3,006,050	0	0	0
Issuance of stock (in shares)	'	1,950,364	'	'	'	'
Interest on subscription receivable	-86	0	0	-86	0	0
Net loss	-1,171,419	0	0	0	0	-1,171,419
Balance at Dec. 31, 2006	1,836,495	5,685	3,004,115	-1,922	0	-1,171,383
Balance (in shares) at Dec. 31, 2006	'	5,685,104	'	'	'	'
Interest on subscription receivable	-71	0	0	-71	0	0
Stock Based Compensation	5,820	0	5,820	0	0	0
Net loss	-979,076	0	0	0	0	-979,076
Balance at Dec. 31, 2007	863,168	5,685	3,009,935	-1,993	0	-2,150,459
Balance (in shares) at Dec. 31, 2007	'	5,685,104	'	'	'	'
Common Stock issued for services	3,858	25	3,833	'	0	0
Common Stock issued for services (in shares)	'	25,060	'	'	'	'
Interest on subscription receivable	-37	0	0	-37	0	0
Stock Based Compensation	16,422	0	16,422	0	0	0
Net loss	-630,859	0	0	0	0	-630,859
Balance at Dec. 31, 2008	252,552	5,710	3,030,190	-2,030	0	-2,781,318
Balance (in shares) at Dec. 31, 2008	'	5,710,164	'	'	'	'
Stock and warrants issued for cash	800,007	437	799,570	0	0	0
Stock and warrants issued for cash (in shares)	'	436,816	'	'	'	'
Interest on subscription receivable	-69	0	0	-69	0	0
Stock Based Compensation	8,251	0	8,251	0	0	0
Net loss	-148,970	0	0	0	0	-148,970
Balance at Dec. 31, 2009	911,771	6,147	3,838,011	-2,099	0	-2,930,288
Balance (in shares) at Dec. 31, 2009	'	6,146,980	'	'	'	'
Stock and warrants issued for cash	2,000,000	1,092	1,998,908	0	0	0
Stock and warrants issued for cash (in shares)	'	1,092,030	'	'	'	'
Equity Offering transaction costs	-91,155	0	-91,155	0	0	0
Interest on subscription receivable	-57	0	0	-57	0	0
Stock Based Compensation	24,163	0	24,163	0	0	0
Net loss	-1,055,748	0	0	0	0	-1,055,748
Balance at Dec. 31, 2010	1,788,974	7,239	5,769,927	-2,156	0	-3,986,036
Balance (in shares) at Dec. 31, 2010	'	7,239,010	'	'	'	'
Issuance of stock	1,000,000	519	999,481	0	0	0
Issuance of stock (in shares)	'	518,714	'	'	'	'
Interest on subscription receivable	-29	0	0	-29	0	0
Stock Based Compensation	15,527	0	15,527	0	0	0
Net loss	-1,149,320	0	0	0	0	-1,149,320
Balance at Dec. 31, 2011	1,655,152	7,758	6,784,935	-2,185	0	-5,135,356
Balance (in shares) at Dec. 31, 2011	'	7,757,724	'	'	'	'
Issuance of stock	5,000,000	2,594	4,997,406	0	0	0
Issuance of stock (in shares)	'	2,593,570	'	'	'	'
Interest on subscription receivable	-26	0	0	-26	0	0
Stock Based Compensation	332,347	0	332,347	0	0	0
Unrealized gain (loss) on marketable securities	-21,795	0	0	0	-21,795	0
Net loss	-2,071,255	0	0	0	0	-2,071,255
Balance at Dec. 31, 2012	4,894,423	10,351	12,114,689	-2,211	-21,795	-7,206,611
Balance (in shares) at Dec. 31, 2012	'	10,351,294	'	'	'	'
Interest on subscription receivable	-1	0	0	-1	0	0
Proceeds from subscription receivable	2,212	0	0	2,212	0	0
Stock Based Compensation	263,593	0	263,593	0	0	0
Reverse acquisition of Nile	3,176,000	1,336	3,174,664	0	0	0
Reverse acquisition of Nile (in shares)	'	1,336,453	'	'	'	'
Unrealized gain (loss) on marketable securities	20,815	0	0	0	20,815	0
Net loss	-8,891,924	0	0	0	0	-8,891,924
Balance at Dec. 31, 2013	-534,882	11,687	15,552,946	0	-980	-16,098,535
Balance (in shares) at Dec. 31, 2013	'	11,687,747	'	'	'	'
Stock Based Compensation	84,544	0	84,544	0	0	0
Unrealized gain (loss) on marketable securities	576	0	0	0	576	0
Stock Option Exercise	933	3	930	0	0	0
Stock Option Exercise (in shares)	3,112	3,112	'	'	'	'
Net loss	-1,210,611	0	0	0	0	-1,210,611
Balance at Mar. 31, 2014	($1,659,440)	$11,690	$15,638,420	$0	($404)	($17,309,146)
Balance (in shares) at Mar. 31, 2014	'	11,690,859	'	'	'	'

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) (USD $)	Dec. 31, 2008	Dec. 31, 2006	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2012	Dec. 31, 2011
	Common Stock [Member]	Series A-1	Series A-2	Series A-2	Series A-3	Series A-3
Share Price	$0.15	$1.54	$1.83	$1.83	$1.93	$1.93

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended		105 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net loss	($1,210,611)	($1,417,114)	($17,309,146)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:	'	'	'
Gain on sale of property and equipment	0	0	-3,707
Depreciation and amortization	6,465	6,120	171,197
Common stock issued for services	0	0	3,858
Impairment of goodwill	0	0	1,919,000
Stock-based compensation	84,544	41,373	750,667
Change in assets - (increase) decrease:	'	'	'
Restricted cash	846,627	-515,222	-555,232
Grants receivable	0	329,240	0
Interest receivable	-570	8,274	-757
Prepaid expenses and other current assets	53,184	7,268	-146,475
Deposits	0	0	-23,193
Change in liabilities - increase (decrease):	'	'	'
Accounts payable and accrued expenses	12,086	165,058	1,251,092
Accounts payable and accrued expenses, related party	99,501	133,094	481,643
Sub-award payable, related party	-41,855	48,317	0
Accrued royalties	9,963	9,963	132,379
Accrued interest	25,327	3,711	83,461
Deferred revenue	11,458,333	3,711	11,458,333
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	11,342,994	-1,176,207	-1,786,880
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Purchase of marketable securities	-226,998	-42,830	-4,668,517
Proceeds from sales and maturities of marketable securities	227,842	488,000	4,341,887
Proceeds from sale of property and equipment	0	0	88,908
Payments for purchase of property and equipment	-92,901	-3,144	-377,824
Proceeds from reverse merger	0	0	664
Payments for patents	-2,257	-10,986	-261,939
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	-94,314	431,040	-876,821
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from loan payable, net	0	857,267	3,925,066
Proceeds from stock option exercises	933	0	933
Costs related to the issuance of preferred stock and warrants	0	0	-91,155
NET CASH PROVIDED BY FINANCING ACTIVITIES	933	857,267	15,642,851
NET INCREASE IN CASH AND CASH EQUIVALENTS	11,249,613	112,100	12,979,150
Cash and cash equivalents balance at beginning of period	1,729,537	170,106	0
Cash and cash equivalents balance at end of period	12,979,150	282,206	12,979,150
SUPPLEMENTAL DISCLOSURES:	'	'	'
Interest paid in cash	0	0	0
Income taxes paid in cash	0	0	0
Series A-1 [Member]	'	'	'
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from the sale of preferred stock	0	0	3,008,000
Series A-2 [Member]	'	'	'
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from the sale of preferred stock	0	0	2,800,007
Series A-3 [Member]	'	'	'
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from the sale of preferred stock	$0	$0	$6,000,000

ORGANIZATION_AND_SUMMARY_OF_SI

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2014
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
		1	ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Description of Business
	The mission of Capricor Therapeutics, Inc., a Delaware corporation (referred to herein as “Capricor Therapeutics” or the “Company”), is to improve the treatment of diseases by commercializing innovative therapies. Capricor, Inc., a privately-held company and a wholly-owned subsidiary of Capricor Therapeutics (referred to herein as “Capricor”), was founded in 2005 as a Delaware corporation based on the innovative work of its founder, Eduardo Marbán, M.D., Ph.D. After completion of a merger between Capricor and Nile Therapeutics, Inc., or Nile, on November 20, 2013, Nile formally changed its name to Capricor Therapeutics, Inc. Capricor Therapeutics, together with its subsidiary, Capricor, currently has six drug candidates in various stages of development.
	Basis of Presentation
	The accompanying unaudited interim condensed consolidated financial statements for Capricor Therapeutics and its wholly-owned subsidiary have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and instructions to Form 10-Q and, therefore, do not include all disclosures necessary for a complete presentation of financial position, results of operations and cash flows in conformity with U.S. GAAP. In the Company’s opinion, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included.  Interim results are not necessarily indicative of the results that may be expected for the entire fiscal year. The accompanying financial information should be read in conjunction with the consolidated financial statements and the consolidated notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 31, 2014, from which the December 31, 2013 consolidated balance sheet has been derived.
	Consummation of Merger
	On November 20, 2013, pursuant to that certain Agreement and Plan of Merger and Reorganization dated as of July 7, 2013, as amended by that certain First Amendment to Agreement and Plan of Merger and Reorganization, dated as of September 27, 2013 (as amended, the “Merger Agreement”), by and among Nile, Bovet Merger Corp., a Delaware corporation and a wholly-owned subsidiary of Nile (“Merger Sub”), and Capricor, Merger Sub merged with and into Capricor and Capricor became a wholly-owned subsidiary of Nile (the “Merger”). Immediately prior to the effective time of the Merger (the “Effective Time”) and in connection therewith, Nile filed certain amendments to its certificate of incorporation which, among other things (i) effected a 1-for-50 reverse split of its common stock (the “Reverse Stock Split”), (ii) changed its corporate name from “Nile Therapeutics, Inc.” to “Capricor Therapeutics, Inc.,” and (iii) effected a reduction in the total number of authorized shares of common stock from 100,000,000 to 50,000,000, and a reduction in the total number of authorized shares of preferred stock from 10,000,000 to 5,000,000.
	At the Effective Time and in connection with the Merger, each outstanding share of Capricor’s Series A-1, Series A-2 and Series A-3 Preferred Stock was converted into one share of common stock, par value $0.001 per share, of Capricor (the “Capricor Common Stock”).
	As a result of the Merger and in accordance with the terms of the Merger Agreement, each outstanding share of Capricor Common Stock was converted into the right to receive approximately 2.07 shares of the common stock of Capricor Therapeutics, par value $0.001 per share (the “Capricor Therapeutics Common Stock”), on a post 1-for-50 Reverse Stock Split basis. Immediately after the Effective Time and in accordance with the terms of the Merger Agreement, the former Capricor stockholders owned approximately 90% of the outstanding common stock of Capricor Therapeutics, and the Nile stockholders owned approximately 10% of the outstanding common stock of Capricor Therapeutics, in each case on a fully-diluted basis. For accounting purposes, the Merger is accounted for as a reverse merger with Capricor as the accounting acquiror (legal acquiree) and Nile as the accounting acquiree (legal acquiror).
	Since Capricor was deemed to be the accounting acquiror in the merger, the historical financial information for periods prior to the Merger reflect the financial information and activities solely of Capricor and not of Nile. The historical equity of Capricor has been retroactively adjusted to reflect the equity structure of Capricor Therapeutics using the respective exchange ratio established in the Merger, which reflects the number of shares Capricor Therapeutics issued to equity holders of Capricor as a result of the Merger. The retroactive adjustment of Capricor’s equity includes Capricor’s preferred stock as if such shares of preferred stock had been converted into Capricor common stock at the respective dates of issuance, which is consistent with the terms of the Merger. Accordingly, all common and preferred shares and per share amounts for all periods presented in the condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q and consolidated notes thereto have been adjusted retrospectively, where applicable, to reflect the respective exchange ratio established in the Merger.
	After the Effective Time, each then outstanding Capricor stock option, whether vested or unvested, was assumed by Capricor Therapeutics in accordance with the terms of (i) the 2006 Stock Option Plan, (ii) the 2012 Restated Equity Incentive Plan, or (iii) the 2012 Non-Employee Director Stock Option Plan, as applicable, and the stock option agreement under which each such option was issued. All rights with respect to Capricor Common Stock under outstanding Capricor options were converted into rights with respect to Capricor Therapeutics Common Stock.
	Basis of Consolidation
	Our condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.
	Development Stage Activities
	The Company is a development stage enterprise since it has not yet generated any revenue from the sale of products and, through March 31, 2014, its efforts have been principally devoted to developing its licensed technologies, recruiting personnel, developing its intellectual property portfolio and raising capital. Accordingly, the accompanying financial statements have been prepared in accordance with the provisions of Accounting Standards Codification (“ASC”) 915, “Development Stage Entities.” The Company has experienced net losses since its inception and had an accumulated deficit of approximately $17.3 million at March 31, 2014. The Company expects to incur substantial and increasing losses and have negative net cash flows from operating activities as it expands its technology portfolio and engages in further research and development activities, particularly the conducting of pre-clinical and clinical trials.
	Liquidity
	The Company has historically financed its research and development activities as well as operational expenses from equity financings, government grants, a payment from Janssen Biotech, Inc. (“Janssen”) and a loan award from the California Institute for Regenerative Medicine (“CIRM”).
	Cash resources consisting of cash, cash equivalents and marketable securities as of March 31, 2014 were approximately $13.3 million, compared to $2.1 million as of December 31, 2013. On January 7, 2014, Capricor received $12.5 million from Janssen pursuant to the terms of the Collaboration Agreement and Exclusive License Option entered into on December 27, 2013 by and between the Company and Janssen (the “Janssen Agreement”). The Company will need substantial additional financing in the future until it can achieve profitability, if ever. The Company’s continued operations will depend on its ability to raise additional funds through various potential sources, such as equity and debt financing, or to license its compounds to another pharmaceutical company. The Company will continue to fund operations from cash on hand and through sources of capital similar to those previously described, as well as government funded grants and/or loans.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents.
	Restricted Cash
	As of March 31, 2014 and December 31, 2013, restricted cash represents funds received under Capricor’s Loan Agreement with CIRM (see note 2), to be allocated to the ALLSTAR clinical trial research costs as incurred.
	Marketable Securities
	At March 31, 2014 and December 31, 2013, marketable securities consist primarily of United States treasuries. These investments are considered available-for-sale. Realized gains and losses on the sale of debt and equity securities are determined on the specific identification method. Unrealized gains and losses are presented as other comprehensive income (loss).
	Intangible Assets
	As a result of the Merger, the Company recorded $1.5 million as in-process research and development, a component of intangible assets. As of March 31, 2014, the Company had not begun amortizing the in-process research and development.
	Government Research Grants
	Government research grants that provide funding for research and development activities are recognized as income when the related expenses are incurred, as applicable.
	Income from Collaborative Agreement
	Revenue from nonrefundable, up-front license or technology access payments under license and collaborative arrangements that are not dependent on any future performance by the Company is recognized when such amounts are earned. If the Company has continuing obligations to perform under the arrangement, such fees are recognized over the estimated period of continuing performance obligation.
	The Company accounts for multiple element arrangements, such as license and development agreements in which a customer may purchase several deliverables, in accordance with Financial Accounting Standards Board (“FASB”) ASC Subtopic 605-25, “Multiple Element Arrangements”. For new or materially amended multiple element arrangements, the Company identifies the deliverables at the inception of the arrangement and each deliverable within a multiple deliverable revenue arrangement is accounted for as a separate unit of accounting if both of the following criteria are met: (1) the delivered item or items have value to the customer on a standalone basis and (2) for an arrangement that includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially in the Company’s control. The Company allocates revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable using vendor-specific objective evidence (“VSOE”) of selling price, if it exists, or third-party evidence (“TPE”) of selling price, if it exists. If neither VSOE nor TPE of selling price exist for a deliverable, the Company uses the best estimated selling price for that deliverable. Revenue allocated to each element is then recognized based on when the basic four revenue recognition criteria are met for each element.
	The Company determined the deliverables under its collaborative arrangement with Janssen (see note 7) did not meet the criteria to be considered separate accounting units for the purposes of revenue recognition. As a result, the Company recognized revenue from non-refundable, upfront fees ratably over the term of its performance under the agreement. The upfront payments received, pending recognition as revenue, are recorded as deferred revenue and are classified as a short-term or long-term liability on the consolidated balance sheets and amortized over the estimated period of performance. The Company periodically reviews the estimated performance period of its contract based on the progress of its project.
	Goodwill
	The Company calculates goodwill as the difference between the acquisition date fair value of the estimated consideration paid in the Merger and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is generally subject to an impairment test annually or more frequently if an event or circumstance indicates that an impairment loss may have been incurred. The Company determined the goodwill balance of $1.9 million to be impaired as of December 31, 2013, and charged such amount to other expenses.
	Loan Payable
	The Company accounts for the funds advanced under its Loan Agreement with CIRM (see note 2) as a loan payable as the eventual repayment of the loan proceeds or forgiveness of the loan is contingent upon certain future milestones being met and other conditions. As the likelihood of whether or not the Company will ever achieve these milestones or satisfy these conditions cannot be reasonably predicted at this time, the Company records these amounts as a loan payable.
	Research and Development
	Costs relating to the design and development of new products are expensed as research and development as incurred in accordance with FASB ASC 730-10, Research and Development. Research and development costs amounted to approximately $1.4 million, $1.2 million and $12.9 million for the three months ended March 31, 2014 and 2013 and for the period from July 5, 2005 (inception) through March 31, 2014, respectively.
	Comprehensive Income (Loss)
	Comprehensive income (loss) generally represents all changes in stockholders’ equity during the period except those resulting from investments by, or distributions to, stockholders. For the three months ended March 31, 2014 and 2013 and for the period from July 5, 2005 (inception) through March 31, 2014, the Company’s comprehensive income (loss) was $576, $(8,763), and $(404), respectively. The Company’s other comprehensive income (loss) is related to a net unrealized gain (loss) on marketable securities.
	Earnings (Loss) per Share
	Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares, which primarily consist of stock options issued to employees and warrants issued to third parties, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.
	For the three months ended March 31, 2014 and 2013, warrants and options to purchase 5,041,281 and 5,813,078 shares, respectively, have been excluded from the computation of potentially dilutive securities.
	Fair Value Measurements
	Assets and liabilities recorded at fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories are as follows:
	Level Input:		Input Definition:
	Level I		Inputs are unadjusted, quoted prices for identical assets or liabilities in  active markets at the measurement date.
	Level II		Inputs, other than quoted prices included in Level I, that are observable  for the asset or liability through corroboration with market data at the  measurement date.
	Level III		Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the  measurement date.
	The following table summarizes fair value measurements by level at March 31, 2014 and December 31, 2013 for assets and liabilities measured at fair value on a recurring basis:
			March 31, 2014
			Level I		Level II		Level III		Total
	Marketable securities		$	326,226	$	-	$	-	$	326,226
			December 31, 2013
			Level I		Level II		Level III		Total
	Marketable securities		$	326,494	$	-	$	-	$	326,494
	Carrying amounts reported in the balance sheet of cash and cash equivalents, grants receivable and accounts payable and accrued expenses approximate fair value due to their relatively short maturity. The carrying amounts of the Company’s marketable securities approximate fair value based on market quotations from national exchanges at the balance sheet date. Interest and dividend income are recognized separately on the income statement based on classifications provided by the brokerage firm holding the investments. The fair value of borrowings is not considered to be significantly different than its carrying amount because the stated rates for such debt reflect current market rates and conditions.
	Warrant Liability
	The Company accounts for some of its warrants issued in accordance with the guidance on Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, which provides that the Company classifies the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. The fair value of warrants is estimated by management using Black-Scholes. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as a component of other income or expense. Prior to the Merger, the Company and holders of warrants to purchase shares of common stock entered into agreements pursuant to which such holders agreed to receive an aggregate of 59,546 shares of the Company’s common stock in exchange for the cancellation and surrender of their warrants. No proceeds were received by the Company from these issuances. Management has determined the value of the warrant liability to be insignificant at March 31, 2014, and no such liability has been reflected on the balance sheet.
	New Accounting Pronouncements
	In February 2013, the FASB issued Accounting Standards Update (“ASU”) 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, (“ASU 2013-02”). ASU 2013-02 amends ASC 220, Comprehensive Income (“ASC 220”), and requires entities to present the changes in the components of accumulated other comprehensive income for the current period. Entities are required to present separately the amount of the change that is due to reclassifications, and the amount that is due to current period other comprehensive income. These changes are permitted to be shown either before or net-of-tax and can be displayed either on the face of the financial statements or in the footnotes. ASU 2013-02 was effective for our interim and annual periods beginning January 1, 2013. The adoption of ASU 2013-02 did not have a material effect on our consolidated financial position or results of operations.
In March 2013, the FASB issued new guidance related to the release of cumulative translation adjustment related to an entity’s investment in a foreign entity. The guidance clarifies that the guidance in Subtopic 830-30, Foreign Currency Matters - Translation of Financial Statements, applies to the release of cumulative translation adjustment into net income when a reporting entity either sells a part or all of its investment in a foreign entity or ceases to have a controlling financial interest in a subsidiary or group of assets that constitute a business within a foreign entity. This guidance is effective for the Company prospectively for reporting periods beginning October 1, 2014. The adoption of this guidance is not expected to have a material impact on the Company’s condensed consolidated financial statements.
In April 2013, the FASB issued ASU 2013-07, Presentation of Financial Statements (Topic 205): Liquidation Basis of Accounting. ASU 2013-07 clarifies when an entity should apply the liquidation basis of accounting. ASU 2013-07 also provides principles for the recognition and measurement of assets and liabilities and requirements for financial statements prepared using the liquidation basis of accounting. ASU 2013-07 is effective for fiscal years and interim periods within those years beginning after December 15, 2013. The Company does not expect amendments in ASU 2013-07 to impact the Company’s condensed consolidated financial statements, results of operations or liquidity.
In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, which eliminates diversity in practice for the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss or a tax credit carryforward is available to reduce the taxable income or tax payable that would result from disallowance of a tax position. ASU 2013-11 affects only the presentation of such amounts in an entity’s balance sheet and is effective for fiscal years beginning after December 15, 2013 and interim periods within those years. The adoption of ASU 2013-11 did not have a material effect on the Company’s consolidated financial position or results of operations.
For a more detailed listing of our significant accounting policies, see Note 1 of the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission on March 31, 2014.

LOAN_PAYABLE

LOAN PAYABLE	3 Months Ended
	Mar. 31, 2014
LOAN PAYABLE	'
		2	LOAN PAYABLE
	On February 5, 2013, Capricor entered into a Loan Agreement with CIRM (the “CIRM Loan Agreement”), pursuant to which CIRM agreed to disburse $19,782,136 to Capricor over a period of approximately three and one-half years to support Phase II of the ALLSTAR clinical trial.
	Under the CIRM Loan Agreement, Capricor is required to repay the CIRM loan with interest at the end of the loan period. The loan also provides for the payment of a risk premium whereby Capricor is required to pay CIRM a premium of up to 500% of the loan amount upon the achievement of certain revenue thresholds. The loan has a term of five years and is extendable annually up to ten years at Capricor’s option if certain conditions are met. The interest rate for the initial term is set at the one-year LIBOR rate plus 2% (“base rate”), compounded annually, and becomes due at the end of the fifth year. After the fifth year, if the term of the loan is extended and if certain conditions are met, the interest rate will increase by 1% over the base rate each sequential year thereafter, with a maximum increase of 5% over the base rate in the tenth year. CIRM has the right to cease disbursements if a no-go milestone occurs or certain other conditions are not met. Under the terms of the CIRM Loan Agreement, CIRM deducted $36,667 from the initial disbursement to cover its costs in conducting financial due diligence on Capricor. CIRM will also deduct approximately $16,667 from each disbursement made in the second and third year of the loan period to cover its costs of continuing due diligence according to the payment disbursement schedule, which may be amended from time to time. So long as Capricor is not in default under the terms of the CIRM Loan Agreement, the loan may be forgiven during the term of the project period if Capricor abandons the trial due to the occurrence of a no-go milestone. After the end of the project period, the loan may also be forgiven if Capricor elects to abandon the project under certain circumstances. Under the terms of the CIRM Loan Agreement, Capricor is required to meet certain financial milestones by demonstrating to CIRM prior to each disbursement of loan proceeds that it has funds available sufficient to cover all costs and expenses anticipated to be required to continue Phase II of the ALLSTAR trial for at least the following 12-month period, less the costs budgeted to be covered by planned loan disbursements.
	The timing of the distribution of funds pursuant to the CIRM Loan Agreement shall be contingent upon the availability of funds in the California Stem Cell Research and Cures Fund in the State Treasury, as determined by CIRM in its sole discretion.
	Capricor did not issue stock, warrants or other equity to CIRM in connection with this award. The due diligence costs to be deducted from each disbursement are capitalized and amortized to general and administrative expenses over the remaining term of the loan. As of March 31, 2014, $36,667 of loan costs were capitalized with $1,834, $1,414, and $8,556 expensed for the three months ended March 31, 2014 and 2013, and the period from July 5, 2005 (inception) through March 31, 2014, respectively, with the balance of $28,111 to be amortized over the next 3.9 years.
	On February 6, 2013, Capricor received loan proceeds of $857,267, net of loan costs. This disbursement will carry interest at the initial rate approximately 2.8% per annum.
	On July 8, 2013, Capricor received its second disbursement under the loan award of $3,067,799. This disbursement will carry interest at the initial rate of approximately 2.5% per annum. A portion of the principal disbursed under the second disbursement is currently being recorded as restricted cash, as Capricor must expend for approved project costs in order to use these funds. For the three months ended March 31, 2014 and 2013 and for the period from July 5, 2005 (inception) through March 31, 2014, interest expense under the CIRM loan was $25,327, $3,711, and $83,461, respectively.

STOCKHOLDERS_EQUITY

STOCKHOLDER'S EQUITY	3 Months Ended
	Mar. 31, 2014
STOCKHOLDER'S EQUITY	'
	3	STOCKHOLDERS’ EQUITY
	Reverse Stock Split
	On November 20, 2013, the Company effected a reverse split of our common stock, par value $0.001 per share, at a ratio of one-for-fifty. Unless otherwise indicated, all share amounts, per share data, share prices, exercise prices and conversion rates set forth in these condensed consolidated financial statements and related condensed consolidated notes, where applicable, have been adjusted retroactively to reflect this reverse stock split.
	Outstanding Shares
	At March 31, 2014, the Company had 11,690,859 common shares issued and outstanding.
	Conversion of all Convertible Preferred Stock at the Merger
	Prior to the Merger and without giving effect to the applicable multiplier, Capricor was authorized to issue 5,426,844 shares of convertible preferred stock, which was allocated as follows: Series A-1: 940,000 shares, all of which were issued; Series A-2: 736,844 shares, all of which were issued; and Series A-3: 3,750,000 shares, of which 1,500,000 shares were issued. During 2011 and 2012, the 1,500,000 shares of Series A-3 convertible preferred stock, with a par value of $0.001 per share, were issued for cash proceeds of $6,000,000. Immediately prior to the Effective Time, all shares of Capricor preferred stock were converted into shares of Capricor common stock pursuant to the terms of the Merger Agreement. The shares of Capricor preferred stock that were converted into Capricor common stock, as a result of the Merger and in accordance with the terms of the Merger Agreement, were exchanged according to the applicable multiplier for 6,591,494 shares of common stock of the Company, and all rights and preferences (including dividends) attached to the shares of Capricor preferred stock were rendered void. The preferred shares are presented retrospectively as shares of common stock on an as-converted basis.

STOCK_OPTIONS_AND_WARRANTS

STOCK OPTIONS AND WARRANTS	3 Months Ended
	Mar. 31, 2014
STOCK OPTIONS AND WARRANTS	'
		4	STOCK OPTIONS AND WARRANTS
	Warrants
	The following table summarizes all warrant activity for the period ended March 31, 2014:
			Warrants		Weighted Average
					Exercise Price
	Outstanding at January 1, 2014		332,281		$	17.2
	Granted		-			-
	Exercised		-			-
	Outstanding at March 31, 2014		332,281		$	17.2
	The following table summarizes all outstanding warrants to purchase shares of the Company’s common stock as of March 31, 2014:
	At March 31, 2014
	Grant Date		Warrants		Range of Exercise			Expiration
			Outstanding		Prices			Date
	7/15/09		28,400			$62.50 - $114.00		7/14/14
	4/21/10		52,650		$	47		4/20/15
	4/4/12		187		$	2.27		4/3/17
	11/20/13		251,044		$	2.27		11/19/18
			332,281
	Stock Options
	The Company’s Board of Directors (the “Board”) has approved four stock option plans: (i) the Amended and Restated 2005 Stock Option Plan, (ii) the 2006 Stock Option Plan, (iii) the 2012 Restated Equity Incentive Plan (which has superseded the 2006 Stock Option Plan) (the “2012 Plan”), and (iv) the 2012 Non-Employee Director Stock Option Plan (the “2012 Non-Employee Director Plan”).
	On July 26, 2010, the Company’s stockholders approved an amendment to the 2005 Plan increasing the total number of shares authorized for issuance thereunder to 190,000 (after the effects of the Reverse Stock Split at the consummation of the Merger). Under the 2005 Plan, incentives may be granted to officers, employees, directors, consultants and advisors. Incentives under the 2005 Plan may be granted in any one or a combination of the following forms: (i) incentive stock options and non-statutory stock options, (ii) stock appreciation rights, (iii) stock awards, (iv) restricted stock, and (v) performance shares.
	After the effects of the Merger, 4,149,710 shares of common stock are reserved under the 2012 Plan for the issuance of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and other service providers. Included in the 2012 Plan are the shares of common stock that were originally reserved under the 2006 Stock Option Plan. Under the 2012 Plan, each stock option granted will be designated in the Award Agreement as either an Incentive Stock Option or a Nonstatutory Stock Option. Notwithstanding such designation, however, to the extent that the aggregate fair market value of the shares with respect to which Incentive Stock Options are exercisable for the first time by the participant during any calendar year (under all plans of the Company and any parent or subsidiary) exceeds $100,000, such options will be treated as Nonstatutory Stock Options.
	After the effects of the Merger, 2,697,311 shares of common stock are reserved under the 2012 Non-Employee Director Plan for the issuance of stock options to members of the Board who are not employees of the Company.
	Each of the plans are administered by the Board, or a committee appointed by the Board, which determines the recipients and types of awards to be granted, as well as the number of shares subject to the awards, the exercise price and the vesting schedule. Currently, stock options are granted with an exercise price equal to the closing price of the Company’s common stock on the date of grant, and generally vest over a period of one to four years. The term of stock options granted under each of the plans cannot exceed ten years.
	The estimated weighted average fair values of the options granted during the three months ended March 31, 2014 and 2013 were $10.65 and $0.25 per share, respectively.
	The Company estimates the fair value of each option award using the Black-Scholes option-pricing model. The following assumptions we used for stock options issued for the three months ended March 31, 2014 and 2013:
			March 31, 2014		March 31, 2013
	Expected volatility		117%		100%
	Expected term		7 years		6-7 years
	Dividend yield		0%		0%
	Risk-free interest rates		2.20%		0.7% - 1.3%
	Employee stock-based compensation expense for the three months ended March 31, 2014 and 2013, and for the cumulative period from July 5, 2005 (inception) through March 31, 2014, are as follows:
							Period from July 5, 2005
							(inception) through
			Three months ended March 31,				March 31, 2014
			2014		2013
	General and administrative		79,260		41,373		745,383
	Research and development		5,284		-		5,284
	Total		84,544		41,373		750,667
	As of March 31, 2014, the total unrecognized fair value compensation cost related to non-vested stock options was approximately $828,035, which is expected to be recognized over approximately 2.9 years.
	Common stock, stock options or other equity instruments issued to non-employees (including consultants) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued (unless the fair value of the consideration received can be more reliably measured). The fair value of stock options is determined using the Black-Scholes option-pricing model and is periodically re-measured as the underlying options vest. The fair value of any options issued to non-employees is recorded as expense over the applicable vesting periods.
	The following table summarizes stock option activity for the three months ended March 31, 2014:
				Number of		Weighted Average
				Options		Exercise Price
	Outstanding at January 1, 2014			4,888,519		$	0.51
	Granted			25,362			12
	Exercised			-3,112			0.3
	Expired			-201,769			0.3
	Outstanding at March 31, 2014			4,709,000		$	0.58
	Exercisable at March 31, 2014			2,719,483		$	0.65

CONCENTRATIONS

CONCENTRATIONS	3 Months Ended
	Mar. 31, 2014
CONCENTRATIONS	'
	5	CONCENTRATIONS
	Cash Concentration
	The Company has historically maintained checking accounts at two financial institutions. These accounts are each insured by the Federal Deposit Insurance Corporation for up to $250,000. Historically, the Company has not experienced any significant losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents. As of March 31, 2014, the Company maintained approximately $13.6 million of uninsured deposits.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2014
COMMITMENTS AND CONTINGENCIES	'
		6	COMMITMENTS AND CONTINGENCIES
	Leases
	Capricor leases space for its corporate offices pursuant to a lease that is effective for a two year period beginning July 1, 2013. The monthly payment is $16,620 per month for the first twelve months of the term and will increase to $17,285 per month for the second twelve months of the term. Capricor also leases research facilities from Cedars-Sinai Medical Center (“CSMC”), a shareholder of the Company, currently on a month-to-month basis.
	Total rent expense to unrelated parties for the three months ended March 31, 2014 and 2013 and for the period from July 5, 2005 (inception) through March 31, 2014 was $49,860, $26,940 and $266,178, respectively. Total rent expense to the related party for the three months ended March 31, 2014 and 2013 and for the period from July 5, 2005 (inception) through March 31, 2014 was $13,662, $13,662 and $336,996, respectively.
	Legal Contingencies
	Periodically the Company may become involved in certain legal actions and claims arising in the ordinary course of business. There were no material legal actions or claims reported at March 31, 2014.

LICENSE_AGREEMENTS

LICENSE AGREEMENTS	3 Months Ended
	Mar. 31, 2014
LICENSE AGREEMENTS	'
		7	LICENSE AGREEMENTS
	Capricor’s Technology - CAP-1002, CAP-1001 and CSps
	Capricor has entered into exclusive license agreements for intellectual property rights related to cardiac derived cells with Università Degli Studi Di Roma at la Sapienza (the “University of Rome”), The Johns Hopkins University (“JHU”) and CSMC. In addition, Capricor has filed patent applications related to enhancements or validation of the technology developed by its own scientists.
	University of Rome License Agreement
	Capricor and the University of Rome entered into a License Agreement, dated June 21, 2006 (the “Rome License Agreement”), which provides for the grant of an exclusive, world-wide, royalty-bearing license by the University of Rome to Capricor (with the right to sublicense) to develop and commercialize licensed products under the licensed patent rights in all fields. With respect to any new or future patent applications assigned to the University of Rome utilizing cardiac stem cells in cardiac care, Capricor has a first right of negotiation for a certain period of time to obtain a license thereto.
	Pursuant to the Rome License Agreement, Capricor paid the University of Rome a license issue fee, is currently paying minimum annual royalties in the amount of 20,000 Euros per year, and is obligated to pay a lower-end of a mid-range double-digit percentage on all royalties received as a result of sublicenses granted, which are net of any royalties paid to third parties under a license agreement from such third party to Capricor. The minimum annual royalties are creditable against future royalty payments.
	The Rome License Agreement will, unless extended or sooner terminated, remain in effect until the later of the last claim of any patent or until any patent application comprising licensed patent rights has expired or been abandoned. Under the terms of the Rome License Agreement, either party may terminate the agreement should the other party become insolvent or file a petition in bankruptcy. Either party shall have up to 90 days to cure its material breach.
	The Johns Hopkins University License Agreement
	Capricor and JHU entered into an Exclusive License Agreement, effective June 22, 2006 (the “JHU License Agreement”), which provides for the grant of an exclusive, world-wide, royalty-bearing license by JHU to Capricor (with the right to sublicense) to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how. In May 2009, the JHU License Agreement was amended to add additional patent rights to the JHU License Agreement in consideration of a payment to JHU and reimbursement of patent costs. Capricor and JHU executed a Second Amendment to the JHU License Agreement, effective as of December 20, 2013, pursuant to which, among other things, certain definitions were added or amended, the timing of certain obligations was revised and other obligations of the parties were clarified.
	Pursuant to the JHU License Agreement, JHU was paid an initial license fee and, thereafter, Capricor is required to pay minimum annual royalties on the anniversary dates of the JHU License Agreement. The minimum annual royalties range from $5,000 on the first and second anniversary dates to $20,000 on the tenth anniversary date and thereafter. The minimum annual royalties are creditable against a low single-digit running royalty on net sales of products and net service revenues which Capricor is also required to pay under the JHU License Agreement, which running royalty may be subject to further reduction in the event that Capricor is required to pay royalties on any patent rights to third parties in order to make or sell a licensed product. In addition, Capricor is required to pay a low double-digit percentage of the consideration received by it from sublicenses granted, and is required to pay JHU certain defined development milestone payments upon the successful completion of certain phases of its clinical studies and upon receiving approval from the U.S. Food and Drug Administration (the “FDA”). The development milestones range from $100,000 upon successful completion of a full Phase I clinical study to $1,000,000 upon full FDA market approval and are fully creditable against payments owed by Capricor to JHU on account of sublicense consideration attributable to milestone payments received from a sublicensee. The maximum aggregate amount of milestone payments payable under the JHU License Agreement, as amended, is $1,850,000. As of March 31, 2014, $100,000 is currently accrued due the Phase I enrollment being completed.
	The JHU License Agreement will, unless sooner terminated, continue in effect in each applicable country until the date of expiration of the last to expire patent within the patent rights, or, if no patents are issued, then for twenty years from the effective date. Under the terms of the JHU License Agreement, either party may terminate the agreement should the other party become insolvent or file a petition in bankruptcy, or fail to cure a material breach within 30 days after notice. In addition, Capricor may terminate for any reason upon 60 days’ written notice.
	Cedars-Sinai Medical Center License Agreement
	On January 4, 2010, Capricor entered into an Exclusive License Agreement with CSMC (the “CSMC License Agreement”), for certain intellectual property rights. In 2013, the CSMC License Agreement was amended twice resulting in, among other things, a reduction in the percentage of sublicense fees which would have been payable to CSMC. Effective December 30, 2013, Capricor entered into an Amended and Restated Exclusive License Agreement with CSMC (the “Amended CSMC License Agreement”) pursuant to which, among other things, certain definitions were added or amended, the timing of certain obligations was revised and other obligations of the parties were clarified.
	The Amended CSMC License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor (with the right to sublicense) to conduct research using the patent rights and know-how and develop and commercialize products in the field using the patent rights and know-how. In addition, Capricor has the exclusive right to negotiate for an exclusive license to any future rights arising from related work conducted by or under the direction of Dr. Eduardo Marbán on behalf of CSMC. In the event the parties fail to agree upon the terms of an exclusive license, Capricor shall have a non-exclusive license to such future rights, subject to royalty obligations.
	Pursuant to the CSMC License Agreement, CSMC was paid a license fee and Capricor was obligated to reimburse CSMC for certain fees and costs incurred in connection with the prosecution of certain patent rights. Additionally, Capricor was equired to meet certain spending and development milestones. The annual spending requirements range from $350,000 to $800,000 each year between 2010 and 2017 (with the exception of 2014, for which there is no annual spending requirement). Pursuant to the Amended CSMC License Agreement,  Capricor remains obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a low double-digit percentage of the consideration received from any sublicenses or other grant of rights. The above-mentioned royalties are subject to reduction in the event Capricor becomes obliged to obtain a license from a third party for patent rights in connection with the royalty-bearing product. In 2010, Capricor discontinued its research under some of the patents.
	The Amended CSMC License Agreement will, unless sooner terminated, continue in effect on a country by country basis until the last to expire of the patents covering the patent rights or future patent rights. Under the terms of the Amended CSMC License Agreement, unless waived by CSMC, the agreement shall automatically terminate: (i) if Capricor ceases, dissolves or winds up its business operations; (ii) in the event of the insolvency or bankruptcy of Capricor or if Capricor makes an assignment for the benefit of its creditors; (iii) if performance by either party jeopardizes the licensure, accreditation or tax exempt status of CSMC or the agreement is deemed illegal by a governmental body; (iv) within 30 days for non-payment of royalties; (v) within 90 days if Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (vi) if a material breach has not been cured within 90 days; or (vii) if Capricor challenges any of the CSMC patent rights. Capricor may terminate the agreement if CSMC fails to cure any material breach within 90 days after notice.
	Collaboration Agreement with Janssen Biotech, Inc.
	On December 27, 2013, Capricor entered into a Collaboration Agreement and Exclusive License Option (the “Janssen Agreement”) with Janssen, a wholly-owned subsidiary of Johnson & Johnson. Under the terms of the Janssen Agreement, Capricor and Janssen agreed to collaborate on the development of Capricor’s cell therapy program for cardiovascular applications, including its lead product, CAP-1002. Capricor and Janssen further agreed to collaborate on the development of cell manufacturing in preparation for future clinical trials. Under the Janssen Agreement, Capricor was paid $12.5 million, and Capricor will contribute to the development of a chemistry, manufacturing and controls (“CMC”) package. In addition, Janssen has the exclusive right to enter into an exclusive license agreement pursuant to which Janssen would receive a worldwide, exclusive license to exploit CAP-1002 as well as certain allogeneic cardiospheres and cardiosphere-derived cells in the field of cardiology. Janssen has the right to exercise the option at any time until 60 days after the delivery by Capricor of the six-month follow-up results from Phase II of Capricor’s ALLSTAR clinical trial for CAP-1002. If Janssen exercises its option rights, Capricor would receive an upfront license fee and additional milestone payments which may total up to $325 million. In addition, a royalty ranging from a low double-digit percentage to a lower-end of a mid-range double-digit percentage would be paid on sales of licensed products.
	Company’s Technology – Cenderitide and CU-NP
	The Company has entered into an exclusive license agreement for intellectual property rights related to natriuretic peptides with the Mayo Foundation for Medical Education and Research and a Clinical Trial Funding Agreement with Medtronic, Inc., which also includes certain intellectual property licensing provisions.
	Mayo License Agreement
	The Company and the Mayo Foundation for Medical Education and Research (“Mayo”) previously entered into a Technology License Agreement with respect to cenderitide on January 20, 2006, which was filed as Exhibit 10.6 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on September 21, 2007, and which was amended on June 2, 2008 (as so amended, the “CD-NP Agreement”). On June 13, 2008, the Company and Mayo entered into a Technology License Agreement with respect to CU-NP (the “CU-NP Agreement”, which was filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2008. On November 14, 2013, the Company entered into an Amended and Restated License Agreement with Mayo (the “Amended Mayo Agreement”). The Amended Mayo Agreement amends and restates in its entirety each of the CD-NP Agreement and the CU-NP Agreement, and creates a single amended and restated license agreement between the Company and Mayo with respect to CD-NP and CU-NP.
	The Amended Mayo Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by Mayo to the Company (with the right to sublicense) under the Mayo patents, patent applications and improvements, and a nonexclusive right under the know-how, for the development and commercialization of CD-NP and CU-NP in all therapeutic indications. With respect to any future patents and any improvements related to cenderitide and CU-NP owned by or assigned to Mayo, the Company has the exclusive right of first negotiation for the exclusive or non-exclusive rights (at the Company’s option) thereto. Such exclusive right of negotiation shall be effective as of June 1, 2016, or such earlier date when the Company has satisfied certain payment obligations to Mayo.
	Under each of the previous CD-NP Agreement and CU-NP Agreement, the Company paid Mayo up-front cash payments and the Company agreed to make certain performance-based cash payments to Mayo upon successful completion of certain milestones. Additionally, the Company issued certain amounts of common stock of the Company to Mayo under each agreement. The Amended Mayo Agreement restructured the economic arrangements of the CD-NP Agreement and CU-NP Agreement by, among other things, eliminating certain milestone payments and decreasing the royalty percentages payable upon the commercial sale of the products to low single-digit royalties on sales of CD-NP and CU-NP products. The Company is also obligated to pay to Mayo a low single-digit percentage on any upfront consideration or milestone payment received in connection with a sublicense. The Company is further obligated to pay to Mayo a low single-digit percentage on any consideration received in connection with an assignment of rights under the Amended Mayo Agreement. Pursuant to the terms of the Amended Mayo Agreement, the Company agreed to pay to Mayo an annual license maintenance fee and to issue to Mayo an additional 18,000 shares of the Company’s common stock as additional consideration for the grant of certain rights. Mayo also agreed to waive or defer the payment of certain fees owed to Mayo. All breaches and defaults by the Company under the terms of the CD-NP Agreement and CU-NP Agreement were waived by Mayo in the Amended Mayo Agreement.
	The Amended Mayo Agreement will, unless sooner terminated, expire on the later of (i) the expiration of the last to expire valid claim contained in the Mayo patents, or (ii) the 20th anniversary of the Amended Mayo Agreement. Under the terms of the Amended Mayo Agreement, Mayo may terminate the agreement earlier (i) for the Company’s material breach of the agreement that remains uncured after 90 days’ written notice to the Company, (ii) for the Company’s insolvency or bankruptcy, (iii) if the Company challenges the validity or enforceability of any of the patent rights in any manner, or (iv) if the Company has not initiated either the next clinical trial of cenderitide within two years of the effective date of the Amended Mayo Agreement or a clinical trial of CU-NP within two and one-half years of the effective date. The Company may terminate the Amended Mayo Agreement without cause upon 90 days’ written notice.
	Medtronic Clinical Trial Funding Agreement
	In February 2011, the Company entered into a Clinical Trial Funding Agreement with Medtronic, Inc. (“Medtronic”). Pursuant to the agreement, Medtronic provided funding and equipment necessary for the Company to conduct a Phase I clinical trial to assess the pharmacokinetics and pharmacodynamics of cenderitide when delivered to heart failure patients through continuous subcutaneous infusion using Medtronic’s pump technology.
	The agreement provided that intellectual property conceived in or otherwise resulting from the performance of the Phase I clinical trial will be jointly owned by the Company and Medtronic (the “Joint Intellectual Property”), and that the Company is to pay royalties to Medtronic based on the net sales of a product covered by the Joint Intellectual Property.  The agreement further provided that, if the parties fail to enter into a definitive commercial license agreement with respect to cenderitide, each party will have a right of first negotiation to license exclusive rights to any Joint Intellectual Property.
	Pursuant to its terms, the agreement expired in February 2012, following the completion of the Phase I clinical trial and the delivery of data and reports related to such study. Nile received the final reimbursement of $195,500 in February 2012 and a total of $1,550,000 over the life of the agreement. Although the Medtronic agreement expired, there are certain provisions that survive the expiration of the agreement, including the obligation to pay royalties on products that might be covered by the Joint Intellectual Property. Neither party has exercised its right to negotiate for exclusive rights to the Joint Intellectual Property.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2014
RELATED PARTY TRANSACTIONS	'
	8	RELATED PARTY TRANSACTIONS
	Lease and Sub-Lease Agreements
	Capricor leases space for its research facilities from CSMC, a shareholder of Capricor Therapeutics (see note 6).
	Beginning May 1, 2012, pursuant to a sublease agreement, Capricor subleased part of its office space to Frank Litvack, the Company’s Executive Chairman, for $2,500 per month. On April 1, 2013, Capricor entered into a sublease with Reprise Technologies, LLC, a limited liability company which is wholly-owned by Dr. Litvack, for $2,500 per month. The sublease is on a month-to-month basis. Capricor recognized $7,500, $7,500 and $57,500 in sublease income from the related party for the three months ended March 31, 2014 and 2013 and for the period from July 5, 2005 (inception) through March 31, 2014, respectively. Sublease income is recorded as a reduction to general and administrative expenses.
	Consulting Agreements
	Effective May 1, 2012, Frank Litvack, the Company’s Executive Chairman, entered into a consulting agreement with Capricor for $4,000 per month for consulting services. Effective January 1, 2013, the payment amount was increased to $10,000 per month payable for consulting services. On March 24, 2014, Capricor entered into a consulting agreement with Dr. Litvack memorializing the $10,000 per month compensation arrangement described above. The agreement is terminable upon 30 days’ notice.
	Sub-Award Agreement
	Effective January 30, 2012, Capricor entered into a sub-award agreement with CSMC. Sub-award payments totaling approximately $41,855, $41,339 and $545,754 were paid to CSMC for the three months ended March 31, 2014 and 2013 and for the period from July 5, 2005 (inception) through March 31, 2014, respectively. At March 31, 2014, the Company did not have any sub-awards payable as the award agreement with CSMC ended pursuant to its terms.
	Payables to Related Party
	At March 31, 2014 and December 31, 2013, the Company had accounts payable and accrued expenses, which excludes the sub-award payable, to CSMC totaling $481,643 and $382,142, respectively.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2014
SUBSEQUENT EVENTS	'
	9	SUBSEQUENT EVENTS
	Additional CIRM Loan Disbursement
	In May 2014, Capricor received its third loan disbursement from CIRM under the terms of the CIRM loan award (see note 2). Capricor received an amount equal to $ 4,679,947  pursuant to the third loan disbursement. This disbursement will carry interest at the initial rate of approximately 2.6% per annum.
	Exosomes License Agreement
	On May 5, 2014, Capricor entered into an Exclusive License Agreement with CSMC (the “Exosomes License Agreement”), for certain intellectual property rights related to exosomes technology. The Exosomes License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor (with the right to sublicense) in order to conduct research using the patent rights and know-how and to develop and commercialize products in the field using the patent rights and know-how. In addition, Capricor has the exclusive right to negotiate for an exclusive license to any future rights arising from related work conducted by or under the direction of Dr. Eduardo Marbán on behalf of CSMC. In the event the parties fail to agree upon the terms of an exclusive license, Capricor shall have a non-exclusive license to such future rights, subject to royalty obligations.
	Pursuant to the Exosomes License Agreement, CSMC was paid a license fee and Capricor reimbursed CSMC for certain fees and costs incurred in connection with the prosecution of certain patent rights. Additionally, Capricor is required to meet certain non-monetary development milestones and is obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a single-digit percentage of the consideration received from any sublicenses or other grant of rights. The above-mentioned royalties are subject to reduction in the event Capricor becomes obliged to obtain a license from a third party for patent rights in connection with the royalty bearing product.
	The Exosomes License Agreement will, unless sooner terminated, continue in effect on a country by country basis until the last to expire of the patents covering the patent rights or future patent rights. Under the terms of the Exosomes License Agreement, unless waived by CSMC, the agreement shall automatically terminate: (i) if Capricor ceases, dissolves or winds up its business operations; (ii) in the event of the insolvency or bankruptcy of Capricor or if Capricor makes an assignment for the benefit of its creditors; (iii) if performance by either party jeopardizes the licensure, accreditation or tax exempt status of CSMC or the agreement is deemed illegal by a governmental body; (iv) within 30 days for non-payment of royalties; (v) within 90 days if Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (vi) if a material breach has not been cured within 90 days; or (vii) if Capricor challenges any of the CSMC patent rights. Capricor may terminate the agreement if CSMC fails to cure any material breach within 90 days after notice.
	As noted above and below, Capricor Therapeutics is party to lease agreements with CSMC, which holds more than 10% of the outstanding capital stock of Capricor Therapeutics. Additionally, Dr. Eduardo Marbán, who holds more than 10% of the outstanding capital stock of Capricor Therapeutics, is the Director of the Cedars-Sinai Heart Institute and the Co-founder and Scientific Advisory Board Chairman of Capricor.
	New Facilities Lease with CSMC
	On May 15, 2014, Capricor signed a Facilities Lease with CSMC for two research labs (the “Facilities Lease”).  The Facilities Lease is for a term of three years and replaces the month-to-month lease that was previously in effect between CSMC and Capricor.  The rent expense for the first six-month period is approximately $15,461 per month.  Commencing with the seventh month of the lease term, the rent expense will increase to approximately $19,350 per month. The amount of rent expense is subject to annual adjustments according to increases in the Consumer Price Index. A copy of the Facilities Lease is filed as Exhibit 10.1 to this Quarterly Report on Form 10-Q.

ORGANIZATION_AND_SUMMARY_OF_SI1

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2014
Consummation of Merger	'
	Consummation of Merger
	On November 20, 2013, pursuant to that certain Agreement and Plan of Merger and Reorganization dated as of July 7, 2013, as amended by that certain First Amendment to Agreement and Plan of Merger and Reorganization, dated as of September 27, 2013 (as amended, the “Merger Agreement”), by and among Nile, Bovet Merger Corp., a Delaware corporation and a wholly-owned subsidiary of Nile (“Merger Sub”), and Capricor, Merger Sub merged with and into Capricor and Capricor became a wholly-owned subsidiary of Nile (the “Merger”). Immediately prior to the effective time of the Merger (the “Effective Time”) and in connection therewith, Nile filed certain amendments to its certificate of incorporation which, among other things (i) effected a 1-for-50 reverse split of its common stock (the “Reverse Stock Split”), (ii) changed its corporate name from “Nile Therapeutics, Inc.” to “Capricor Therapeutics, Inc.,” and (iii) effected a reduction in the total number of authorized shares of common stock from 100,000,000 to 50,000,000, and a reduction in the total number of authorized shares of preferred stock from 10,000,000 to 5,000,000.
	At the Effective Time and in connection with the Merger, each outstanding share of Capricor’s Series A-1, Series A-2 and Series A-3 Preferred Stock was converted into one share of common stock, par value $0.001 per share, of Capricor (the “Capricor Common Stock”).
	As a result of the Merger and in accordance with the terms of the Merger Agreement, each outstanding share of Capricor Common Stock was converted into the right to receive approximately 2.07 shares of the common stock of Capricor Therapeutics, par value $0.001 per share (the “Capricor Therapeutics Common Stock”), on a post 1-for-50 Reverse Stock Split basis. Immediately after the Effective Time and in accordance with the terms of the Merger Agreement, the former Capricor stockholders owned approximately 90% of the outstanding common stock of Capricor Therapeutics, and the Nile stockholders owned approximately 10% of the outstanding common stock of Capricor Therapeutics, in each case on a fully-diluted basis. For accounting purposes, the Merger is accounted for as a reverse merger with Capricor as the accounting acquiror (legal acquiree) and Nile as the accounting acquiree (legal acquiror).
	Since Capricor was deemed to be the accounting acquiror in the merger, the historical financial information for periods prior to the Merger reflect the financial information and activities solely of Capricor and not of Nile. The historical equity of Capricor has been retroactively adjusted to reflect the equity structure of Capricor Therapeutics using the respective exchange ratio established in the Merger, which reflects the number of shares Capricor Therapeutics issued to equity holders of Capricor as a result of the Merger. The retroactive adjustment of Capricor’s equity includes Capricor’s preferred stock as if such shares of preferred stock had been converted into Capricor common stock at the respective dates of issuance, which is consistent with the terms of the Merger. Accordingly, all common and preferred shares and per share amounts for all periods presented in the condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q and consolidated notes thereto have been adjusted retrospectively, where applicable, to reflect the respective exchange ratio established in the Merger.
	After the Effective Time, each then outstanding Capricor stock option, whether vested or unvested, was assumed by Capricor Therapeutics in accordance with the terms of (i) the 2006 Stock Option Plan, (ii) the 2012 Restated Equity Incentive Plan, or (iii) the 2012 Non-Employee Director Stock Option Plan, as applicable, and the stock option agreement under which each such option was issued. All rights with respect to Capricor Common Stock under outstanding Capricor options were converted into rights with respect to Capricor Therapeutics Common Stock.
Basis of Consolidation	'
	Basis of Consolidation
	Our condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.
Development Stage Activities	'
	Development Stage Activities
	The Company is a development stage enterprise since it has not yet generated any revenue from the sale of products and, through March 31, 2014, its efforts have been principally devoted to developing its licensed technologies, recruiting personnel, developing its intellectual property portfolio and raising capital. Accordingly, the accompanying financial statements have been prepared in accordance with the provisions of Accounting Standards Codification (“ASC”) 915, “Development Stage Entities.” The Company has experienced net losses since its inception and had an accumulated deficit of approximately $17.3 million at March 31, 2014. The Company expects to incur substantial and increasing losses and have negative net cash flows from operating activities as it expands its technology portfolio and engages in further research and development activities, particularly the conducting of pre-clinical and clinical trials.
Liquidity	'
	Liquidity
	The Company has historically financed its research and development activities as well as operational expenses from equity financings, government grants, a payment from Janssen Biotech, Inc. (“Janssen”) and a loan award from the California Institute for Regenerative Medicine (“CIRM”).
	Cash resources consisting of cash, cash equivalents and marketable securities as of March 31, 2014 were approximately $13.3 million, compared to $2.1 million as of December 31, 2013. On January 7, 2014, Capricor received $12.5 million from Janssen pursuant to the terms of the Collaboration Agreement and Exclusive License Option entered into on December 27, 2013 by and between the Company and Janssen (the “Janssen Agreement”). The Company will need substantial additional financing in the future until it can achieve profitability, if ever. The Company’s continued operations will depend on its ability to raise additional funds through various potential sources, such as equity and debt financing, or to license its compounds to another pharmaceutical company. The Company will continue to fund operations from cash on hand and through sources of capital similar to those previously described, as well as government funded grants and/or loans.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents.
Restricted Cash	'
	Restricted Cash
	As of March 31, 2014 and December 31, 2013, restricted cash represents funds received under Capricor’s Loan Agreement with CIRM (see note 2), to be allocated to the ALLSTAR clinical trial research costs as incurred.
Marketable Securities	'
	Marketable Securities
	At March 31, 2014 and December 31, 2013, marketable securities consist primarily of United States treasuries. These investments are considered available-for-sale. Realized gains and losses on the sale of debt and equity securities are determined on the specific identification method. Unrealized gains and losses are presented as other comprehensive income (loss).
Intangible Assets	'
	Intangible Assets
	As a result of the Merger, the Company recorded $1.5 million as in-process research and development, a component of intangible assets. As of March 31, 2014, the Company had not begun amortizing the in-process research and development.
Government Research Grants	'
	Government Research Grants
	Government research grants that provide funding for research and development activities are recognized as income when the related expenses are incurred, as applicable.
Income from Collaborative Agreement	'
	Income from Collaborative Agreement
	Revenue from nonrefundable, up-front license or technology access payments under license and collaborative arrangements that are not dependent on any future performance by the Company is recognized when such amounts are earned. If the Company has continuing obligations to perform under the arrangement, such fees are recognized over the estimated period of continuing performance obligation.
	The Company accounts for multiple element arrangements, such as license and development agreements in which a customer may purchase several deliverables, in accordance with Financial Accounting Standards Board (“FASB”) ASC Subtopic 605-25, “Multiple Element Arrangements”. For new or materially amended multiple element arrangements, the Company identifies the deliverables at the inception of the arrangement and each deliverable within a multiple deliverable revenue arrangement is accounted for as a separate unit of accounting if both of the following criteria are met: (1) the delivered item or items have value to the customer on a standalone basis and (2) for an arrangement that includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially in the Company’s control. The Company allocates revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable using vendor-specific objective evidence (“VSOE”) of selling price, if it exists, or third-party evidence (“TPE”) of selling price, if it exists. If neither VSOE nor TPE of selling price exist for a deliverable, the Company uses the best estimated selling price for that deliverable. Revenue allocated to each element is then recognized based on when the basic four revenue recognition criteria are met for each element.
	The Company determined the deliverables under its collaborative arrangement with Janssen (see note 7) did not meet the criteria to be considered separate accounting units for the purposes of revenue recognition. As a result, the Company recognized revenue from non-refundable, upfront fees ratably over the term of its performance under the agreement. The upfront payments received, pending recognition as revenue, are recorded as deferred revenue and are classified as a short-term or long-term liability on the consolidated balance sheets and amortized over the estimated period of performance. The Company periodically reviews the estimated performance period of its contract based on the progress of its project.
Goodwill	'
	Goodwill
	The Company calculates goodwill as the difference between the acquisition date fair value of the estimated consideration paid in the Merger and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is generally subject to an impairment test annually or more frequently if an event or circumstance indicates that an impairment loss may have been incurred. The Company determined the goodwill balance of $1.9 million to be impaired as of December 31, 2013, and charged such amount to other expenses.
Loan Payable	'
	Loan Payable
	The Company accounts for the funds advanced under its Loan Agreement with CIRM (see note 2) as a loan payable as the eventual repayment of the loan proceeds or forgiveness of the loan is contingent upon certain future milestones being met and other conditions. As the likelihood of whether or not the Company will ever achieve these milestones or satisfy these conditions cannot be reasonably predicted at this time, the Company records these amounts as a loan payable.
Research and Development	'
	Research and Development
	Costs relating to the design and development of new products are expensed as research and development as incurred in accordance with FASB ASC 730-10, Research and Development. Research and development costs amounted to approximately $1.4 million, $1.2 million and $12.9 million for the three months ended March 31, 2014 and 2013 and for the period from July 5, 2005 (inception) through March 31, 2014, respectively.
Comprehensive Income (Loss)	'
	Comprehensive Income (Loss)
	Comprehensive income (loss) generally represents all changes in stockholders’ equity during the period except those resulting from investments by, or distributions to, stockholders. For the three months ended March 31, 2014 and 2013 and for the period from July 5, 2005 (inception) through March 31, 2014, the Company’s comprehensive income (loss) was $576, $(8,763), and $(404), respectively. The Company’s other comprehensive income (loss) is related to a net unrealized gain (loss) on marketable securities.
Earnings (Loss) per Share	'
	Earnings (Loss) per Share
	Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares, which primarily consist of stock options issued to employees and warrants issued to third parties, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.
	For the three months ended March 31, 2014 and 2013, warrants and options to purchase 5,041,281 and 5,813,078 shares, respectively, have been excluded from the computation of potentially dilutive securities.
Fair Value Measurements	'
	Fair Value Measurements
	Assets and liabilities recorded at fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories are as follows:
	Level Input:	Input Definition:
	Level I	Inputs are unadjusted, quoted prices for identical assets or liabilities in  active markets at the measurement date.
	Level II	Inputs, other than quoted prices included in Level I, that are observable  for the asset or liability through corroboration with market data at the  measurement date.
	Level III	Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the  measurement date.
	The following table summarizes fair value measurements by level at March 31, 2014 and December 31, 2013 for assets and liabilities measured at fair value on a recurring basis:
		March 31, 2014
		Level I		Level II		Level III		Total
	Marketable securities	$	326,226	$	-	$	-	$	326,226
		December 31, 2013
		Level I		Level II		Level III		Total
	Marketable securities	$	326,494	$	-	$	-	$	326,494
	Carrying amounts reported in the balance sheet of cash and cash equivalents, grants receivable and accounts payable and accrued expenses approximate fair value due to their relatively short maturity. The carrying amounts of the Company’s marketable securities approximate fair value based on market quotations from national exchanges at the balance sheet date. Interest and dividend income are recognized separately on the income statement based on classifications provided by the brokerage firm holding the investments. The fair value of borrowings is not considered to be significantly different than its carrying amount because the stated rates for such debt reflect current market rates and conditions.
Warrant Liability	'
	Warrant Liability
	The Company accounts for some of its warrants issued in accordance with the guidance on Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, which provides that the Company classifies the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. The fair value of warrants is estimated by management using Black-Scholes. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as a component of other income or expense. Prior to the Merger, the Company and holders of warrants to purchase shares of common stock entered into agreements pursuant to which such holders agreed to receive an aggregate of 59,546 shares of the Company’s common stock in exchange for the cancellation and surrender of their warrants. No proceeds were received by the Company from these issuances. Management has determined the value of the warrant liability to be insignificant at March 31, 2014, and no such liability has been reflected on the balance sheet.
New Accounting Pronouncements	'
	New Accounting Pronouncements
	In February 2013, the FASB issued Accounting Standards Update (“ASU”) 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, (“ASU 2013-02”). ASU 2013-02 amends ASC 220, Comprehensive Income (“ASC 220”), and requires entities to present the changes in the components of accumulated other comprehensive income for the current period. Entities are required to present separately the amount of the change that is due to reclassifications, and the amount that is due to current period other comprehensive income. These changes are permitted to be shown either before or net-of-tax and can be displayed either on the face of the financial statements or in the footnotes. ASU 2013-02 was effective for our interim and annual periods beginning January 1, 2013. The adoption of ASU 2013-02 did not have a material effect on our consolidated financial position or results of operations.
	In March 2013, the FASB issued new guidance related to the release of cumulative translation adjustment related to an entity’s investment in a foreign entity. The guidance clarifies that the guidance in Subtopic 830-30, Foreign Currency Matters - Translation of Financial Statements, applies to the release of cumulative translation adjustment into net income when a reporting entity either sells a part or all of its investment in a foreign entity or ceases to have a controlling financial interest in a subsidiary or group of assets that constitute a business within a foreign entity. This guidance is effective for the Company prospectively for reporting periods beginning October 1, 2014. The adoption of this guidance is not expected to have a material impact on the Company’s condensed consolidated financial statements.
	In April 2013, the FASB issued ASU 2013-07, Presentation of Financial Statements (Topic 205): Liquidation Basis of Accounting. ASU 2013-07 clarifies when an entity should apply the liquidation basis of accounting. ASU 2013-07 also provides principles for the recognition and measurement of assets and liabilities and requirements for financial statements prepared using the liquidation basis of accounting. ASU 2013-07 is effective for fiscal years and interim periods within those years beginning after December 15, 2013. The Company does not expect amendments in ASU 2013-07 to impact the Company’s condensed consolidated financial statements, results of operations or liquidity.
	In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, which eliminates diversity in practice for the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss or a tax credit carryforward is available to reduce the taxable income or tax payable that would result from disallowance of a tax position. ASU 2013-11 affects only the presentation of such amounts in an entity’s balance sheet and is effective for fiscal years beginning after December 15, 2013 and interim periods within those years. The adoption of ASU 2013-11 did not have a material effect on the Company’s consolidated financial position or results of operations.

ORGANIZATION_AND_SUMMARY_OF_SI2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements	'
	The following table summarizes fair value measurements by level at March 31, 2014 and December 31, 2013 for assets and liabilities measured at fair value on a recurring basis:
		March 31, 2014
		Level I		Level II		Level III		Total
	Marketable securities	$	326,226	$	-	$	-	$	326,226
		December 31, 2013
		Level I		Level II		Level III		Total
	Marketable securities	$	326,494	$	-	$	-	$	326,494

STOCK_OPTIONS_AND_WARRANTS_Tab

STOCK OPTIONS AND WARRANTS (Tables)	3 Months Ended
	Mar. 31, 2014
Warrant	'
Schedule Of Warrant Activity	'
	The following table summarizes all warrant activity for the period ended March 31, 2014:
		Warrants		Weighted Average
				Exercise Price
	Outstanding at January 1, 2014	332,281		$	17.2
	Granted	-			-
	Exercised	-			-
	Outstanding at March 31, 2014	332,281		$	17.2
Outstanding Warrants to Purchase Shares of the Companybs Common Stock	'
	The following table summarizes all outstanding warrants to purchase shares of the Company’s common stock as of March 31, 2014:
	At March 31, 2014
	Grant Date	Warrants		Range of Exercise			Expiration
		Outstanding		Prices			Date
	7/15/09	28,400			$62.50 - $114.00		7/14/14
	4/21/10	52,650		$	47		4/20/15
	4/4/12	187		$	2.27		4/3/17
	11/20/13	251,044		$	2.27		11/19/18
		332,281
Stock Options	'
Stock Options, Valuation Assumptions	'
	The Company estimates the fair value of each option award using the Black-Scholes option-pricing model. The following assumptions we used for stock options issued for the three months ended March 31, 2014 and 2013:
		March 31, 2014		March 31, 2013
	Expected volatility	117%		100%
	Expected term	7 years		6-7 years
	Dividend yield	0%		0%
	Risk-free interest rates	2.20%		0.7% - 1.3%
Employee Stock-based Compensation Costs	'
	Employee stock-based compensation expense for the three months ended March 31, 2014 and 2013, and for the cumulative period from July 5, 2005 (inception) through March 31, 2014, are as follows:
								Period from
								July 5, 2005
								(inception) through
		Three months ended March 31,						March 31, 2014
		2014			2013
	General and administrative		79,260			41,373		745,383
	Research and development		5,284			-		5,284
	Total		84,544			41,373		750,667
Schedule of Summarizing Stock Option Activity	'
	The following table summarizes stock option activity for the three months ended March 31, 2014:
			Number of		Weighted Average
			Options		Exercise Price
	Outstanding at January 1, 2014		4,888,519		$	0.51
	Granted		25,362			12
	Exercised		-3,112			0.3
	Expired		-201,769			0.3
	Outstanding at March 31, 2014		4,709,000		$	0.58
	Exercisable at March 31, 2014		2,719,483		$	0.65

ORGANIZATION_AND_SUMMARY_OF_SI3

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring [Line Items]	'	'
Marketable Securities	$326,226	$326,494
Level 1[Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring [Line Items]	'	'
Marketable Securities	326,226	326,494
Level 2[Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring [Line Items]	'	'
Marketable Securities	0	0
Level 3[Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring [Line Items]	'	'
Marketable Securities	$0	$0

ORGANIZATION_AND_SUMMARY_OF_SI4

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)	1 Months Ended		3 Months Ended		12 Months Ended	105 Months Ended
	Jan. 31, 2014	Nov. 20, 2013	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Mar. 31, 2014
Accounting Policies [Line Items]	'	'	'	'	'	'
Stockholders Equity, Reverse Stock Split	'	'1-for-50	'1-for-50	'	'	'
Common Stock Shares Authorized	'	'	50,000,000	'	50,000,000	50,000,000
Preferred Stock, Shares Authorized	'	'	5,000,000	'	5,000,000	5,000,000
Common Stock, Par or Stated Value Per Share	'	$0.00	$0.00	'	$0.00	$0.00
Development Stage Enterprise, Deficit Accumulated During Development Stage	'	'	$17,309,146	'	$16,098,535	$17,309,146
Research and Development in Process	'	'	1,500,000	'	'	'
Research and Development Expense, Total	'	'	1,374,757	1,191,154	'	12,874,352
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total	'	'	576	-8,763	'	-404
Number of Rights Offer for each Share as per Merger Agreement	'	2.07	'	'	'	'
Cash, Cash Equivalents, and Short-term Investments, Total	'	'	13,300,000	'	2,100,000	13,300,000
Proceeds From Development Fee	12,500,000	'	'	'	'	'
Goodwill, Impairment Loss	'	'	$0	$0	$1,900,000	$1,919,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	'	'	5,041,281	5,813,078	'	'
Warrant [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Common Stock Issued to Certain Warrant Holders for Cancellation of Certain Warrants	'	'	59,546	'	'	'
Capricor stockholders [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Percentage of Holding on Common Stock Effective After Consummation of Merger on Fully Dilutive Basis	'	90.00%	'	'	'	'
Nile stockholders [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Percentage of Holding on Common Stock Effective After Consummation of Merger on Fully Dilutive Basis	'	10.00%	'	'	'	'

LOAN_PAYABLE_Details_Textual

LOAN PAYABLE (Details Textual) (USD $)	0 Months Ended		3 Months Ended		105 Months Ended
	Jul. 08, 2013	Feb. 06, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Feb. 05, 2013
LOAN PAYABLE [Line Items]	'	'	'	'	'	'
Proceeds from Issuance of Long-term Debt, Total	'	'	$0	$857,267	$3,925,066	'
Interest Expense, Total	'	'	25,327	3,711	83,461	'
CIRM Loan Agreement [Member]	'	'	'	'	'	'
LOAN PAYABLE [Line Items]	'	'	'	'	'	'
Debt Instrument, Face Amount	'	'	'	'	'	19,782,136
Maximum Payback Percentage of Loan Amount to be Paid upon Achievement of Certain Revenue Thresholds	'	'	500.00%	'	'	'
Base Rate for Computation of Interest Rate	'	'	2.00%	'	'	'
Increase In Base Rate after Fifth Year for Computation of Interest Rate	'	'	1.00%	'	'	'
Maximum Increase In Base Rate in Tenth Year for Computation of Interest Rate	'	'	5.00%	'	'	'
Annual Amount to be Deducted from Loan for Due Diligence Costs	'	'	16,667	'	16,667	'
Deferred Finance Costs, Noncurrent, Gross	'	'	36,667	'	36,667	'
Amortization of Financing Costs	'	'	1,834	1,414	8,556	'
Deferred Finance Costs, Noncurrent, Net	'	'	28,111	'	28,111	'
Amortization Period of Finance Cost	'	'	'3 years 10 months 24 days	'	'	'
Proceeds from Issuance of Long-term Debt, Total	3,067,799	857,267	'	'	'	'
Debt Instrument, Interest Rate at Period End	2.50%	2.80%	'	'	'	'
Interest Expense, Total	'	'	$25,327	$3,711	$83,461	'

STOCKHOLDERS_EQUITY_Details_Te

STOCKHOLDER'S EQUITY (Details Textual) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Nov. 20, 2013	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Mar. 31, 2014
				Preferred Stock [Member]	Series A-1 [Member]	Series A-2 [Member]	Series A-3 [Member]	Series A-3 [Member]	Series A-3 [Member]	Series A-3 [Member]	Series A-3 [Member]
					Preferred Stock [Member]	Preferred Stock [Member]			Preferred Stock [Member]	Preferred Stock [Member]	Preferred Stock [Member]
Class of Stock [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Preferred Stock, Shares Authorized	5,000,000	5,000,000	'	5,426,844	940,000	736,844	'	'	'	'	3,750,000
Preferred Stock, Shares Issued	0	0	'	'	940,000	736,844	'	'	'	'	1,500,000
Stock Issued During Period, Shares, Conversion of Convertible Securities	'	'	'	'	'	'	'	'	1,500,000	1,500,000	'
Common Stock, Par or Stated Value Per Share	$0.00	$0.00	$0.00	'	'	'	'	'	'	'	'
Preferred Stock, Par or Stated Value Per Share	$0.00	$0.00	'	'	'	'	$0.00	$0.00	'	'	'
Proceeds from Issuance of Preferred Stock and Preference Stock	'	'	'	'	'	'	$6,000,000	$6,000,000	'	'	'
Common Stock Shares Outstanding	11,690,859	11,687,747	'	'	'	'	'	'	'	'	'
Convertible Preferred Stock, Shares Issued upon Conversion	6,591,494	'	'	'	'	'	'	'	'	'	'

STOCK_OPTIONS_AND_WARRANTS_Det

STOCK OPTIONS AND WARRANTS (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Class of Warrant or Right [Line Items]	'
Warrants Outstanding at January 1, 2014	332,281
Warrants Granted	0
Warrants Exercised	0
Warrants Outstanding at March 31, 2014	332,281
Weighted Average Exercise Price Outstanding at January 1, 2014	$17.20
Weighted Average Exercise Price Granted	$0
Weighted Average Exercise Price Exercised	$0
Weighted Average Exercise Price Outstanding at March 31, 2014	$17.20

STOCK_OPTIONS_AND_WARRANTS_Det1

STOCK OPTIONS AND WARRANTS (Details 1)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014
			Period Issuance one [Member]	Period Issuance one [Member]	Period Issuance one [Member]	Period Issuance two [Member]	Period Issuance three [Member]	Period Issuance four [Member]
				Minimum [Member]	Maximum [Member]
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'
Grant Date	'	'	15-Jul-09	'	'	21-Apr-10	4-Apr-12	20-Nov-13
Warrants Outstanding	332,281	332,281	28,400	'	'	52,650	187	251,044
Range of Exercise Prices	'	'	'	62.5	114	47	2.27	2.27
Expiration Date	'	'	14-Jul-14	'	'	20-Apr-15	3-Apr-17	19-Nov-18

STOCK_OPTIONS_AND_WARRANTS_Det2

STOCK OPTIONS AND WARRANTS (Details 2)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'
Expected volatility	117.00%	100.00%
Expected term	'7 years	'
Dividend yield	0.00%	0.00%
Risk-free interest rates	2.20%	'
Maximum [Member]	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'
Expected term	'	'7 years
Risk-free interest rates	'	1.30%
Minimum [Member]	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'
Expected term	'	'6 years
Risk-free interest rates	'	0.70%

STOCK_OPTIONS_AND_WARRANTS_Det3

STOCK OPTIONS AND WARRANTS (Details 3) (USD $)	3 Months Ended		105 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation cost	$84,544	$41,373	$750,667
General and Administrative Expense [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation cost	79,260	41,373	745,383
Research and Development Expense [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation cost	$5,284	$0	$5,284

STOCK_OPTIONS_AND_WARRANTS_Det4

STOCK OPTIONS AND WARRANTS (Details 4) (USD $)	3 Months Ended
	Mar. 31, 2014
Options	'
Outstanding at January 1, 2014	4,888,519
Granted	25,362
Exercised	-3,112
Expired	-201,769
Outstanding at March 31, 2014	4,709,000
Exercisable at March 31, 2014	2,719,483
Exercise Price	'
Outstanding at January 1, 2014	$0.51
Granted	$12
Exercised	$0.30
Expired	$0.30
Outstanding at March 31, 2014	$0.58
Exercisable at March 31, 2014	$0.65

STOCK_OPTIONS_AND_WARRANTS_Det5

STOCK OPTIONS AND WARRANTS (Details Textual) (USD $)	3 Months Ended			1 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2012	Jul. 26, 2010	Dec. 31, 2012
			Non-Employee Director Plan 2012 [Member]	Employee Stock Option [Member]	Employee Stock Option [Member]
				Stock Option Plan 2005 [Member]	Stock Option Plan 2012 [Member]
Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	'	'	'	190,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	'	2,697,311	'	4,149,710
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	'	'	'	'	$100,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$828,035	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'2 years 10 months 24 days	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$10.65	$0.25	'	'	'

CONCENTRATIONS_Details_Textual

CONCENTRATIONS (Details Textual) (USD $)	Mar. 31, 2014
CONCENTRATIONS [Line Items]	'
Cash, FDIC Insured Amount	$250,000
Cash, Uninsured Amount	$13,600,000

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details Textual) (USD $)	3 Months Ended		105 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Commitments and Contingencies Disclosure [Line Items]	'	'	'
Leases Monthly Payments For First Twelve Months	$16,620	'	$16,620
Leases Monthly Payments For Second Twelve Months	17,285	'	17,285
Unrealated Party [Member]	'	'	'
Commitments and Contingencies Disclosure [Line Items]	'	'	'
Operating Leases, Rent Expense	49,860	26,940	266,178
Related party [Member]	'	'	'
Commitments and Contingencies Disclosure [Line Items]	'	'	'
Operating Leases, Rent Expense	$13,662	$13,662	$336,996

LICENSE_AGREEMENTS_Details_Tex

LICENSE AGREEMENTS (Details Textual)

1 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

Jan. 31, 2014

Feb. 29, 2012

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

USD ($)

USD ($)

USD ($)

EUR (€)

JHU License Agreement [Member]

Minimum [Member]

Maximum [Member]

Completion of Phase One [Member]

Obtention of FDA Approval [Member]

Mayo License Agreement [Member]

First and Second Anniversary [Member]

Tenth Anniversary and Thereafter [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

LICENSE AGREEMENTS [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds From Development Fee

$12,500,000

'

'

'

'

'

'

'

'

'

'

'

Additional Milestone Payments to be Received Contingent upon Exercise of Options

'

'

325,000,000

'

'

'

'

'

'

'

'

'

Common Stock Issued as Additional Consideration for Grant of Certain Rights

'

'

'

'

'

'

'

'

'

18,000

'

'

Milestone Payments To be Made Upon Successful Completion of Certain Phases

'

'

'

'

'

'

'

100,000

1,000,000

'

'

'

Accrued Milestone Payments

'

'

'

'

1,850,000

'

'

'

'

'

'

'

Payments for Royalties

'

'

'

20,000

'

'

'

'

'

'

5,000

20,000

Development Milestones

'

'

'

'

'

350,000

800,000

'

'

'

'

'

Reimbursement Revenue

'

$195,500

$1,550,000

'

'

'

'

'

'

'

'

'

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details Textual) (USD $)

Mar. 31, 2014

Dec. 31, 2013

31-May-12

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

31-May-12

Mar. 31, 2014

Dec. 31, 2013

Jan. 31, 2012

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Board of Directors Chairman [Member]

Board of Directors Chairman [Member]

Board of Directors Chairman [Member]

Board of Directors Chairman [Member]

Board of Directors Chairman [Member]

Board of Directors Chairman [Member]

Board of Directors Chairman [Member]

Affiliated Entity [Member]

Affiliated Entity [Member]

Affiliated Entity [Member]

Affiliated Entity [Member]

Affiliated Entity [Member]

Affiliated Entity [Member]

Sublease Agreement with Frank Litvack [Member]

Sublease Agreement with Frank Litvack [Member]

Sublease Agreement with Frank Litvack [Member]

Sublease Agreement with Frank Litvack [Member]

Consulting Agreement with Frank Litvack [Member]

Consulting Agreement with Frank Litvack [Member]

Consulting Agreement with Frank Litvack [Member]

Sub-Award Agreement with CSMC [Member]

Sub-Award Agreement with CSMC [Member]

Sub-Award Agreement with CSMC [Member]

Sub-Award Agreement with CSMC [Member]

Transaction other than Sub-Award Agreement [Member]

Transaction other than Sub-Award Agreement [Member]

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Related Party Transaction, Description of Transaction

'

'

'Beginning May 1, 2012, pursuant to a sublease agreement, Capricor subleased part of its office space to Frank Litvack, the Companys Executive Chairman, for $2,500 per month

'

'

'

'Effective May 1, 2012, Frank Litvack, the Companys Executive Chairman, entered into a consulting agreement with Capricor for $4,000 per month for consulting services

'

'

'Effective January 30, 2012, Capricor entered into a sub-award agreement with CSMC

'

'

'

'

'

Monthly Rent from Related Party

'

'

$2,500

'

'

'

'

'

'

'

'

'

'

'

'

Rental Income, Nonoperating

'

'

'

7,500

7,500

57,500

'

'

'

'

'

'

'

'

'

Monthly Consulting Fees to Related Party

'

'

'

'

'

'

4,000

10,000

'

'

'

'

'

'

'

Increased Monthly Consulting Fees to Related Party

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

Sub-Award Payments

'

'

'

'

'

'

'

'

'

'

41,855

41,339

545,754

'

'

Accounts Payable and Accrued Expenses Related Party Current

$481,643

$382,142

'

'

'

'

'

'

'

'

'

'

'

$481,643

$382,142

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (USD $)	3 Months Ended		105 Months Ended	0 Months Ended		3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Jul. 08, 2013	Feb. 06, 2013	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014
				CIRM Loan Agreement [Member]	CIRM Loan Agreement [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
						CIRM Loan Agreement [Member]	CSMC [Member]	Dr. Eduardo Marban [Member]
Subsequent Event [Line Items]	'	'	'	'	'	'	'	'
Proceeds from Issuance of Long-term Debt, Total	$0	$857,267	$3,925,066	$3,067,799	$857,267	$4,679,947	'	'
Percentage Of Common Stock Shares Outstanding	'	'	'	'	'	'	10.00%	10.00%
Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate	'	'	'	'	'	2.60%	'	'
Increase in Rent Expense	'	'	'	'	'	'	19,350	'
Operating Leases, Rent Expense, Net, Total	'	'	'	'	'	'	$15,461	'
Lease Expiration Period	'	'	'	'	'	'	'3 years	'